Overview

* Amarin Q3 2025 total net revenue rises 17% yr/yr, driven by higher U.S. sales

* Operating expenses fell 20% in Q3 2025 due to restructuring efforts

* Company's operating loss improves, reflecting restructuring impact

Outlook

* Amarin ( AMRN ) targets sustainable positive free cash flow in 2026

* Company expects steady operating margin and cash flow improvements

Result Drivers

* PARTNERED MODEL - Transition to partnered commercialization model in Europe affected sales, per CFO Peter Fishman

* RESTRUCTURING IMPACT - Significant decrease in operating expenses due to restructuring, leading to improved operating margin

* U.S. SALES GROWTH - Higher net selling price and regained exclusive status with a large PBM drove U.S. sales increase

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $49.70

Product mln

Revenue

Q3 $33.29

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "sell" and the breakdown of recommendations is no "strong buy" or "buy", 1 "hold" and 2 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Amarin Corporation PLC ( AMRN ) is $10.00, about 89.4% below its October 28 closing price of $18.94

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)